Phase 2, Randomized, Open-Label Parallel-Group Study of Two Dosing Regimens of Netarsudil for the Treatment of Corneal Edema Due to Fuchs Corneal Dystrophy

BACKGROUND: This phase 2 study evaluated the therapeutic potential of netarsudil to reduce corneal edema and to improve vision in patients with Fuchs corneal dystrophy (FCD). METHODS: Patients (N = 40) with baseline central corneal thickness (CCT) of ≥600 μm and best-corrected visual acuity (BCVA) o...

Descripción completa

Detalles Bibliográficos
Autores principales: Lindstrom, Richard L., Lewis, Amber E., Holland, Edward J., Sheppard, John D., Hovanesian, John A., Senchyna, Michelle, Hollander, David A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc., publishers 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9784611/
https://www.ncbi.nlm.nih.gov/pubmed/36327101
http://dx.doi.org/10.1089/jop.2022.0069

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9784611/
https://www.ncbi.nlm.nih.gov/pubmed/36327101
http://dx.doi.org/10.1089/jop.2022.0069

Ejemplares similares